Cardiac resynchronization therapy improves altered Na channel gating in canine model of dyssynchronous heart failure

Takeshi Aiba1, Andreas S Barth, Geoffrey G Hesketh

  • 1Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Insights

Cardiac resynchronization therapy (CRT) normalizes sodium channel function in heart failure by reducing late sodium current (INa-L), shortening action potential duration, and preventing arrhythmias. This study explores the underlying molecular mechanisms involving CaMKII.

Area of Science:

  • Cardiovascular Physiology
  • Cardiac Electrophysiology
  • Molecular Cardiology

Background:

  • Dyssynchronous heart failure (DHF) is associated with slowed sodium current (INa) decay and enhanced late INa (INa-L), prolonging action potential duration (APD) and causing early afterdepolarizations.
  • Cardiac resynchronization therapy (CRT) shortens APD in DHF, but its effects on Na+ channel gating are not well understood.

Purpose of the Study:

  • To investigate the impact of CRT on Na+ channel gating abnormalities in a canine model of DHF.
  • To explore the role of phosphorylated Ca2+/Calmodulin protein kinase II (pCaMKII) in mediating CRT's effects on Na+ channels.

Main Methods:

  • Adult dogs were subjected to DHF (left-bundle branch ablation and pacing) or CRT (DHF followed by biventricular pacing).
  • INa and INa-L were measured in left ventricular myocytes.
  • A canine action potential model was used to simulate the effects of INa-L alterations.

Main Results:

  • DHF altered Na+ channel availability and slowed recovery from inactivation, while markedly increasing INa-L.
  • CRT reversed some DHF-induced gating changes and dramatically reduced INa-L, abbreviating APD and suppressing early afterdepolarizations.
  • CRT was linked to reduced pCaMKII levels, suggesting a molecular pathway for Na+ channel regulation.

Conclusions:

  • CRT effectively improves DHF-induced Na+ channel dysfunction, particularly by suppressing INa-L, leading to APD abbreviation and reduced early afterdepolarizations.
  • Reduced pCaMKII levels represent a potential molecular mechanism through which biventricular pacing regulates cardiac Na+ channels in heart failure.
Abstract

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...